Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 70 of 6351
-
New hope for colorectal cancer: experimental drug faces off against avastin
Disease control Recruiting nowThe purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, c…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Engineered immune cells take on tough lymphoma in new trial
Disease control Recruiting nowDALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of …
Phase 2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Brain cancer breakthrough? GammaTile trial aims to boost survival
Disease control Recruiting nowThis is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation of Arm A:Arm B. * A Perioperative/Operati…
Phase 3 • Sponsor: GT Medical Technologies, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New COVID-19 vaccine trial targets variants in Middle-Aged adults
Vaccine OngoingThis study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a group that receives a vaccine that doesn't contain an ingredient to protect against COVID-19 (placebo).
Phase 3 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Jun 27, 2026 12:06 UTC
-
Magic Mushroom-Derived drug enters final trial for depression
Symptom relief Recruiting nowThe purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your intere…
Phase 3 • Sponsor: Cybin IRL Limited • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC
-
Pfizer launches massive trial of c. diff vaccine for seniors
Vaccine Recruiting nowThe purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older. The participants will receive either the C. diffici…
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Sep 10, 2026 02:00 UTC
-
New hope for rare lung cancer: targeted pill tepotinib faces final test
Disease control Recruiting nowThe hypothesize is that tepotinib is more effective than the investigator's choice of treatment in patients with MET-mutated NSCLC who have progressed after at least one first-line treatment. The main benefit concerns patient access to tepotinib. There is currently no access to …
Phase 3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New shot could help kids with tough leukemia
Disease control OngoingThe main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
Phase 1/2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo aims to revive immune response in lung cancer
Disease control Recruiting nowTHIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to …
Phase 3 • Sponsor: Maia Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug duo aims to outsmart stomach cancer
Disease control Recruiting nowCIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the survival of patients suffering from MSI-H/dMMR locally advanced or metastatic oeasogastric adenocarcinoma treated by a bi-immunotherapy (experimental arm) versus standard current trea…
Phase 3 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill takes on tough pancreatic cancer in major trial
Disease control Recruiting nowThis study plans to enroll participants with previously treated metastatic pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. These participants are required to experience disease progression on or after at least one prior standard systemic therapy containing fl…
Phase 3 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Supercharged immune cells take on advanced melanoma
Disease control Recruiting nowThis is a phase I/II clinical trial of a single dose of CD40L-augmented TIL administered in patients with advanced melanoma (Cohort 1: Cutaneous acral melanoma, cutaneous non-acral melanoma, (n=26); Cohort 2: Mucosal melanoma, uveal melanoma, (n=10)). Patients will undergo an exc…
Phase 1/2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New asthma drug could cut attacks with just two shots a year
Disease control Recruiting nowThe objective of this study is to assess the potential for GB-0895 treatment to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. The study details include: Study treatment:…
Phase 3 • Sponsor: Generate Biomedicines • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Massive mpox vaccine trial launches in DRC: could it stop the outbreak?
Vaccine Recruiting nowThis is a health facility-based prospective test-negative (TND) case-control study to evaluate vaccine effectiveness and active safety monitoring (cohort event monitoring), and passive surveillance for evaluation of the safety of the LC16m8 mpox vaccine in individuals aged one ye…
Sponsor: International Vaccine Institute • Aim: Vaccine
Last updated Sep 02, 2026 00:00 UTC
-
A simple blood test may catch hidden heart failure before It's too late
Prevention Recruiting nowHeart failure (HF) occurs when the heart is no longer able to pump blood effectively throughout the body. This leads to symptoms that gradually worsen over time and are often mistaken for normal signs of aging. Because of its insidious onset, early detection is challenging. Both …
Sponsor: University Hospital, Basel, Switzerland • Aim: Prevention
Last updated Jul 30, 2026 00:00 UTC
-
Last hope drug trial for kids with fatal brain disease
Disease control OngoingCree Leukoencephalopathy (CLE) is a very rare and severe brain disease that mainly affects members of the Cree communities in Northern Quebec. It causes the white matter of the brain-the part that helps nerves communicate-to slowly break down. As the disease progresses, children …
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New liposomal irinotecan combo takes on pancreatic cancer in major trial
Disease control Recruiting nowThis study is a randomized, open-label, multicenter Phase III clinical trial designed to evaluate the efficacy and safety of Irinotecan Hydrochloride Liposome Injection (II) combined with oxaliplatin and 5-FU/LV versus nab-paclitaxel combined with gemcitabine as first-line treatm…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for pancreatic cancer: dual antibody plus targeted pill tested in major trial
Disease control Recruiting nowThis study adopts a randomized, open label, placebo-controlled, multicenter trial design. OS was the primary endpoint, and eligible subjects were randomly divided into 1:1 groups and received TQB2868 injection and anlotinib hydrochloride capsules combined with chemotherapy, compa…
Phase 3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo aims to outsmart resistant bladder cancer
Disease control Recruiting nowThis phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan-hziy to standard of care in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metas…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Bladder cancer trial pits radiotherapy against standard immunotherapy
Disease control Not yet recruitingIn the UK 20,000 people develop urothelial bladder cancer each year with 75-80% having Non-Muscle Invasive Bladder Cancer (NMIBC). The current standard of care for patients with High Risk-NMIBC (HR-NMIBC) is either surgery to remove the tumour (transurethral resection of bladder …
Phase 3 • Sponsor: The Christie NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC